They represent new target molecules for AD therapy, together with TSLP, IL-4, and IL-31, that could dampen Th2 responses regulating the immune cell proliferation and stimulation of sensory cutaneous neurons to transmit itch sensation (38, 39). Here, IL31 is linked to Alzheimer disease.